Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates

REMAIN-1 Pivotal Cohort met its six-month co-primary endpoint with high statistical significance (p=0.0023); Revita® participants retained approximately 80% of GLP-1-induced weight loss versus 67% for shamPlanned FDA De Novo submission in late Q4 2026; topline 12-month data from the REMAIN-1 Pivota…